FUJIFILM
22
32M
20
0.24
3
0.09
3
- Areas of investment
Summary
FUJIFILM is the famous Corporate Investor, which was founded in 1934. The fund was located in Asia if to be more exact in Japan. The leading representative office of defined Corporate Investor is situated in the Tokyo.
Among the most popular portfolio startups of the fund, we may highlight Century Therapeutics, EdiGene, Lyndra Therapeutics. Besides, a startup needs to be aged 2-3 years to get the investment from the fund. Among the most successful fund investment fields, there are Pharmaceutical, Medical Device. For fund there is no match between the location of its establishment and the land of its numerous investments - United States. The fund has no specific favorite in a number of founders of portfolio startups. If startup sums 3 or 5+ of the founder, the chance for it to be financed is low.
The top activity for fund was in 2017. The real fund results show that this Corporate Investor is 30 percentage points more often commits exit comparing to other companies. The usual things for fund are deals in the range of 10 - 50 millions dollars. The fund is generally included in 2-6 deals every year.
The typical case for the fund is to invest in rounds with 3-4 participants. Despite the FUJIFILM, startups are often financed by Polaris Partners, Yonghua Capital, Toray Industries. The meaningful sponsors for the fund in investment in the same round are SBI Investment, Cyberdyne, Yonghua Capital. In the next rounds fund is usually obtained by Lilly Asia Ventures, IDG Capital, WI Harper Group.
Investments analytics
Analytics
- Total investments
- 22
- Lead investments
- 3
- Exits
- 3
- Rounds per year
- 0.24
- Follow on index
- 0.09
- Investments by industry
- Biotechnology (12)
- Health Care (11)
- Medical (9)
- Medical Device (9)
- Manufacturing (3) Show 24 more
- Investments by region
-
- United States (5)
- Japan (13)
- Israel (1)
- China (1)
- Australia (1) Show 1 more
- Peak activity year
- 2017
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 9
- Avg. valuation at time of investment
- 46M
- Group Appearance index
- 0.64
- Avg. company exit year
- 8
- Avg. multiplicator
- 5.57
- Strategy success index
- 0.70
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Tome Biosciences | 12 Dec 2023 | Biotechnology, Genetics, Medical | Early Stage Venture | 213M | United States, Massachusetts, Watertown |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.